Meeting
2020 Gastrointestinal Cancers Symposium
Irinotecan, cetuximab, and bevacizumab (CBI) versus irinotecan, cetuximab, and placebo (CI) in irinotecan-refractory metastatic colorectal cancer (mCRC): Results from an ACCRU network randomized phase II trial.
Authors
Marla Lipsyc-Sharf
Department of Internal Medicine, Brigham and Women's Hospital, Boston, MA
Marla Lipsyc-Sharf , Fang-Shu Ou , Matthew B. Yurgelun , Douglas Adam Rubinson , Deborah Schrag , Shaker R. Dakhil , Philip J. Stella , Douglas Jay Weckstein , Donald B. Wender , Meredith Gail Faggen , Tyler Zemla , Erica N. Heying , Samantha R Schuetz , Stephanie Noble , Jeffrey A. Meyerhardt , Tanios S. Bekaii-Saab , Charles S. Fuchs , Kimmie Ng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Anal and Colorectal Cancer
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02292758
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 102)
Abstract #
102
Poster Bd #
E10
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A multicenter randomized phase II trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study.
First Author: Hideaki Bando
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2021 ASCO Annual Meeting
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2021 Gastrointestinal Cancers Symposium
Safety analysis of the randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13).
First Author: Takanori Watanabe